Skip to main content
Equibles
ARTL logo

ARTL · Artelo Biosciences, Inc. · Executive Compensation

Track ARTL — free

Use ARTL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ARTL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.56 -0.06 (-2.29%) At close · Oct 21
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.”
View the 10-Q filed Aug 12, 2026
Market Cap
$1.37M
Shares
510,563
Volume · Oct 21 17.45K Avg daily vol (37 sessions) 789.99K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

No Compensation Data

No Summary Compensation Table has been imported from this company's proxy statements yet.

Executive changes

Person Change Filed
Mark Spring Appointed 2025-10-27

Leadership

Key facts CIK 1621221 CUSIP 04301G805 13F (30d) 1 filings 1 filers Visit website Investor relations